We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
- Authors
Von Hoff, Daniel D; Ramanathan, Ramesh K; Borad, Mitesh J; Laheru, Daniel A; Smith, Lon S; Wood, Tina E; Korn, Ronald L; Desai, Neil; Trieu, Vuong; Iglesias, Jose L; Zhang, Hui; Soon-Shiong, Patrick; Shi, Tao; Rajeshkumar, N V; Maitra, Anirban; Hidalgo, Manuel
- Abstract
The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and safety data. Additional objectives were to evaluate positron emission tomography (PET) scan response, secreted protein acidic and rich in cysteine (SPARC), and CA19-9 levels in relation to efficacy. Subsequent preclinical studies investigated the changes involving the pancreatic stroma and drug uptake.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 34, p4548
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.36.5742